85%Confidence
0Views
FDASource
2026-04-21Date
Summary
Fresenius Kabi's sterility recall extends to a 500mL sodium chloride injection, further indicating widespread manufacturing issues. This could strain its production capacity and lead to increased costs for remediation and quality control.
Actionable: Analyze Fresenius Kabi's ability to maintain supply commitments and the risk of contract losses to competitors.
AI Confidence: 85%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL) 500 mL in a Single Dose freeflex bag, 500 mL x 20, Manufactured for: Fresenius Kab
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now